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NEOPLASIA
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Oncogenic activation of tyrosine kinase
signaling pathway is recurrent in human
leukemia. To gain insight into the onco-
genic process leading to acute
megakaryoblastic leukemia (AMKL), we
performed sequence analyses of a subset
of oncogenes known to be activated in
human myeloid and myeloproliferative
disorders. In a series of human AMKL
samples from both Down syndrome and
non–Down syndrome patients, mutations
were identified within KIT, FLT3, JAK2,
JAK3, and MPL genes, with a higher fre-
quency in DS than in non-DS patients.
The novel mutations were analyzed using
BaF3 cells, showing that JAK3 mutations
were activating mutations. Finally, we re-
port a novel constitutively active MPL
mutant, MPLT487A, observed in a non–
Down syndrome childhood AMKL that
induces a myeloproliferative disease in
mouse bone marrow transplantation as-
say. (Blood. 2008;112:4220-4226)
Introduction
Acute megakaryoblastic leukemia (AMKL) is a heterogeneous
subtype of acute myeloid leukemia (AML) with diverse genetic
and morphologic characteristics. The estimated frequency of
AMKL ranges from 3% to 14% of AML, and is more frequent in
children than in adults.1 Approximately 65% of AMKLs are
associated with myelofibrosis.1,2 In adults, AMKL is frequently
observed as secondary leukemia after chemotherapy or leukemic
transformation of several chronic myeloproliferative disorders
(MPDs) including chronic myelogenous leukemia (CML), polycythe-
mia vera (PV), essential thrombocytosis (ET), and idiopathic myelofibro-
sis (IMF).3-5 Recently, point mutations have been described within the
JAK2 gene in MPD and within the gene coding for the thrombopoietin
receptor (MPL) in a subset of myelofibrosis and ET.6-9
Access to primary AMKL cells is extremely limited due in part
to severe myelofibrosis in many cases that precludes bone marrow
aspiration, and to its prevalence in pediatric populations. In
childhood AMKL, 2 major subgroups have nevertheless been
described that include patients with constitutional trisomy 21
associated with GATA1 mutations,10 and those with the t(1;22)(p13;
q13) translocation encoding the OTT-MAL (RBM15-MKL1) fu-
sion protein.11-13
Several observations suggest that these latter genetic mutations
may not be sufficient to cause an AMKL phenotype. For example,
although most Down syndrome (DS) patients with constitutional
trisomy 21 and GATA1 mutations present with a transient myelopro-
liferative disorder (TMD) at or around birth, there is spontaneous
remission of the TMD and absence of further malignant disease in
most instances.14 In addition, in humans, patients with inherited
GATA1 mutation (similar to those observed in TMD and AMKL)
do not develop leukemia.15 Similarly, expression of a mutant
GATA-1s protein in a knockin mouse model is able to induce a
transient hyperproliferation of yolk sac and fetal liver megakaryo-
cyte progenitors, but is not sufficient to induce AMKL per se.16
These observations indicate that there are multigenic contributions
to the development of AMKL.
Constitutive tyrosine phosphorylation of STAT5 has been
described in a significant proportion of cases of AML. In several
instances, the molecular basis for the constitutive activation of
STAT5 is known to be due to activating mutations in tyrosine
kinases, including internal tandem duplication (ITD) and activation loop
mutations in FLT3, as well as activating mutations in KIT.17,18 Although
FLT3 mutations have been identified in a broad spectrum of AML,
mutations in tyrosine kinases are rarely reported in AMKL.19-24
In search for activating mutations, we systematically analyzed
the sequences coding for selected domains in proteins involved in
the control of tyrosine kinase activity and known to be mutated in
human AML and MPD.
Methods
Samples and sequencing
Patients with DS- and non–DS-AMKL have been described previously25 and are
summarized in Table 1. No material was available from patients with the t(1;22)
translocation. cDNAs were amplified using HotStar DNA polymerase (Qiagen,
Courtaboeuf, France). Research was approved by the INSERM review board and
conducted in accordance with the Declaration of Helsinki.
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Primers were as follows: JH1-JAK2 I (TTCTTTCAGAGCCATCAT-
ACG; TATATTTCTCGTTGCCAGATCC); JH1-JAK2 II (TGCAAGGG-
TATGGAGTATCTTG; CTACTTTGGTCTCAGAATGAAGG); JH2-JAK2
I (GTCCCCCAAAGCCAAAAGATAAAT; TGTAATACTAATGCC-
AGGATCAC); JH2-JAK2 II (CTTATTCATGGGAATGTATGTGCC;
TCTCTTCAAACTGTGTAGGATCC); SH2a-JAK2 (CCGAGTTGTAAC-
TATCCATAAG; AGTAGGCCTCTGTAATGTTGG); JH2-JAK3 I (AATC-
CCAATACCAGCTGAG; GGATCCTGTCGGTGAGCAT); JH2-JAK3 II
(GGAGCCCGCCCTTCATCA; TGCCGCTATGACCCGCTA); JH2-JAK3
III (CCTAAGGCAGGTCTGTGAGC; GAGGTGGGAAGAACAGCCTA);
JH2-JAK3 IV (ACAGAGGTGCTGCTGAAGGT; CCACGTTTTCGCA-
GATACAT); SH2-JAK3 V (GCTACTTCCGGCTGACCAC; ACCACCT-
CATGGCGACAG); MPL I (TCGCTACCGTTTACAGCTGC; ACTTGGG-
GAGGATTTCAAGG); MPL II (GTTAGGGCGCTCTATCCTGTTG;
Table 1. AMKL samples analyzed for KIT, FLT3, JAK2, JAK3, and MPL mutations
Patient no. Age Sex % Blasts Karyotype
GATA-1
mutations
JAK2, JAK3, FLT3, KIT,
and MPL changes
Down syndrome
AMKL
11 10m F 22 Random aberration,21c  
15 14m M 31 48,XY,8,21c nd FLT3 D835Y
16 15m F 20 na nd JAK3 V722I
18 13m F 43 47,XX,21c,del(6q)  
19 11m F 14 4446,XX,4,9,16,21ccp7/47,XX,21c7 nd FLT3 D835Y
20 8m F 80 Random aberration  JAK2 V617F
30 18m M na 47,XX,21c/49,XX,inv(9)(p11;q12),21c,21c,21c  
Non-AMKL
58 (TMD) 2d F 14 47,XX,21c  
85 (TMD) 1m M na 47,XY,2119/46,XY3  
60 (AML) 24m M 88 47,XY,21c  
63 (AML) 24m F 59 47,XX,21c  
Non–Down syndrome
Child AMKL
69 1d M 90 21a  FLT3-ITD
24 51m M 58 Random aberration nd MPL T487A
28 8m F 57 46, XX nd KIT D816V
29 11y M 46 45,XY,inv(3)(q21q23),7 nd 
31 13m M na 47XY,2,15,19,t(7;8) nd JAK2 M535I
33 16m M 31 46, XY  
34 33m M 40 46, XY  
35 20m F 73 47,XX,34/46,XX21  
36 30m M 80 46,XY,random aberration7/46,XY15  
37 36m M 74 46,XY,add(2)(q37),ins(3;?)(q21;?),del(5)(q13q22),
7,9,add(16)(q24),min,mar
 
38 24m F 60 46,XX,del(9)(p21)1/46,X,t(X;21)(q24;q21),del(9)(p21),
1919
 
41 7m M 47 64-65,XY,t(1;8)(p32;q24),2,3,4,5,6,8,9,
10,19,20,22
 
44 8m M na 6, XY20  
45 3m M 73 6, XY20  
46 26y M 15 nd  
47 38m M 72 nd nd 
49 11m M 80 nd  
66 14m F 83 46,XX,der(5),der(6),t(6;17)(p22;q22) del(6)(p22-pter)der(7)
t(5;7)(?q;q31)del(7)(q31-qter),der(17)t(5;17)(?q;q22)20
 
83 22m M 83 nd nd 
86 6y M 86 46,XY nd 
Adult AMKL
48 62y F 62 nd  
39 58y M 70 46,XY,3,5,del(7)(q21q33),der(20) t(3;20)(q23;q12),
21,222/88,XYY,X,Y,4,5,5,6,7,8,
9,9,11,del(12)(p12),13,14,16,17,18,19,
19,der(20)t(3;20)x2,21,2118
 
54 40y F 42 nd nd 
71 67y M 50 nd nd 
72 47y M 90 Complex aberrations nd 
74 76y F 60 46,XX nd 
82 45y M 71 nd  
84 38y M na nd  
DS-AMKL 20m M 40 na  JAK2V617F
Cell lines
CMK 10m M Complex hypotetraploid karyotype  JAK3A572V
CMY M Complex hypotetraploid karyotype  JAK3A573V
na indicates not available; and nd, not determined.
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AGTCCCTGGCGCAGGCGCTGT); KIT (GGATGACGAGTTGGC-
CCTAGA; GTAGAACTTAGAATCGACCGGCA); KIT-JM (AAACT-
CATCTGGGCCACCGTTT; CACTCGGCTTGAGCATCTTT); KIT-EC
(ACCGAAGGAGGCACTTACAC; TACATTCAACCGTGCCATTG);
FLT3 I (GCAATTTAGGTATGAAAGCCAGC; CTTTCAGCATTTT-
GACGGCAACC); FLT3 II (GAAGATCTTCTTTGCTTTGC; TATGACCA-
GACATCACTCTT); and FLT3 III (TTGCAATCATAAGCACCAGCC;
AAGTACTCATTATCTGAGGAGCC).
Plasmids
The JAK2 expression vector has been previously described.26 The JAK3 and
MPL sequences were polymerase chain reaction (PCR) amplified from a human
wild-type cDNA template and subcloned in MSCV-IRES-GFP. Mutations were
generated using the Quickchange kit (Stratagene, Amsterdam, The Netherlands).
All constructions were verified by sequence analyses.
Cell culture
Murine interleukin-3 (IL-3)–dependent BaF3 cells were grown with 5%
WEHI-conditioned medium (WCM) as a source of IL-3. Cells were
electroporated and GFP-positive cells were sorted by flow cytometry after
6 days of culture. Cytokine-independent growth assays and serum starva-
tion experiments were performed as described.26 Cell growth was moni-
tored using a PCA-96 Easycyte (Guava Technologies, Hayward, CA).
Western blot analysis
Cells were lysed and separated by electrophoresis as described previously.26 All
antibodies were from Cell Signaling (Ozyme, St Quentin-en-Yvelines, France)
except the anti-MPL antibody (Millipore, St Quentin-en-Yvelines, France).
Bone marrow transplantation and mice analysis
This study received INSERM review board approval for the use of mice.
Viral supernatants were obtained as described.27 Briefly, 6- to 8-week-old
BALB/c donor mice were injected with fluorouracil (5-FU) 5 days prior to
bone marrow collection. Primary bone marrow cells were obtained from
femurs and tibiae. Suspensions were depleted of lineage marker–expressing
cells (BD Biosciences, Le Pont de Claix, France) and cultured for 2 days in
RPMI1640 supplemented with 10% fetal bovine serum in the presence
of murine recombinant IL-3 (10 ng/mL), IL-6 (10 ng/mL), and SCF
(100 ng/mL; all from PromoCell, Heidelberg, Germany).
Cells were mixed with viral supernatants on day 3 and day 4 and
spinfected for 90 minutes at 1800g each time. After the second spinfection,
1.5  105 cells were injected into the retro orbital veins of lethally
irradiated BALB/c recipients. At the time of injection, efficiency of
retroviral transduction was assessed by GFP expression by flow cytometry
and ranged from 40% to 50%. Eye bleeds were performed using EDTA or
heparin-coated capillary tubes and blood counts were performed within
30 minutes on a MS9-5V (Melet Schloesing, Cergy-Pontoise, France). At
the time of final analysis (30 days max after transplantation), the percentage
of GFP-positive cells in the blood remained the same as at the time of
injection for MPLWT (50%), but increased to 95% or more in MPLW515L
and MPLT487A animals, suggesting positive selection. When possible,
MPLT487A and MPLWT animals were analyzed simultaneously.
Staining for flow cytometry was performed in PBS. All antibodies were
obtained from BD Biosciences, except the CD42b antibody obtained from
Emfret (Eibelstadt, Germany). Acquisition of the data was performed on a
CyanADP (Dako, Trappes, France) and analyzed with Summit software
(Dako). For colony-forming assays, primary mouse bone marrow or spleen
cells were collected and were subsequently treated with red blood cell lysis
buffer. For myeloid colony assays, cells were plated in MethoCult 3434 or
MethoCult 3231 (StemCell Technologies, Grenoble, France) and colonies
were scored at day 7. For megakaryocytic progenitor colony assays,
2  105 bone marrow cells were mixed with MegaCult-C (StemCell
Technologies) containing Tpo, IL-11, IL-3, and IL-6 and plated onto
double-chamber culture slides; colonies were enumerated at day 7, after
acetylcholinesterase staining.
Results
We investigated 11 DS and 28 non–DS-AMKL samples by
nucleotide sequence analysis of cDNA. Because of the limited
amount of material available, only selected exons were analyzed
from PCR-amplified cDNA, including the sequences coding for the
juxtamembrane regions and the activation loops of FLT3 and KIT;
the regions encoding the JH1 and JH2 regions of JAK2 and the JH2
and SH2 regions of JAK3, where activating mutations have been
described; and the MPL sequences coding for the protein segment
spanning the membrane. The observed nucleotide sequence changes
are shown in Figure 1 and Figure S1 (available on the Blood
website; see the Supplemental Materials link at the top of the online
article) and are summarized Table 1.
No sequence changes were observed in non–DS AMKL samples.
Three mutations were observed in FLT3: 1 ITD (patient 69) and
2 mutations leading to D to Y amino acid substitution at position
835 (D835Y; patients DS15 and DS19). One example of KIT
mutation was observed in a non-DS patient (D816V; patient 28).
Two changes in the JAK2 cDNA were also observed, resulting in
M535I (patient 31) and V617F (patient DS20). A V722I was
observed in JAK3 in patient DS16. Regarding MPL, no changes
were observed within the codon coding W515 in our series.
However a nonsynonymous nucleotide change was observed in a
non-DS patient (patient 24), leading to a T to A substitution at
amino acid 487. No remission material was available.
Taken together, 3 unambiguous mutations were observed in
each subgroup (DS and non-DS patients). Although the number of
patients is very small, the frequency of activating mutations within
these genes seems higher in AMKL from DS patients (57%) with
respect to non-DS patients (11%).
Three additional mutations have been identified. A JAK2V617F
was observed in another DS-AMKL patient (Figure S1), unrelated
to the above-mentioned series. Within JAK3, a A573V change was
observed in the cell line CMY and a A572V change in CMK
(Figure 1B). Sequence analyses showed an higher quantity of the
mutated JAK3 allele, with respect to wild type, when starting from
Figure 1. Mutations of JAK2, JAK3, and MPL in AMKL samples and cell lines.
Mutations of JAK2 M535I (A) and MPL T487A (C) were found in children with
non–Down syndrome AMKL. Mutations of JAK3 A572V and JAK3 A573V were found
in CMK and CMY cell lines, respectively (B).
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cDNA or from genomic DNA (Figure S2A). In keeping with these
results, fluorescent in situ hybridization (FISH) analyses demon-
strated the presence of 3 JAK3 loci in the cells (data not shown),
suggesting the mutated allele has been duplicated. These 2 leu-
kemic cell lines were established from DS-AMKL samples.28,29
We next evaluated the newly identified amino acid changes
functionally for their potential to confer cytokine-independent cell
growth to BaF3 cells. MSCV-GFP constructs expressing
JAK3A572V, JAK3A573V, JAK3V722I, JAK2M535I,
JAK2V617F, and MPLT487A were transduced in the murine
IL3-dependent BaF3 cell line and growth of sorted GFP-positive
cells was tested in the absence of cytokine (Figure 2).
When tested in that assay, JAK2M535I was neither able to
stimulate the growth of BaF3 in the absence of IL3, nor able to
detectably activate signaling effectors (Figure 3A), suggesting that
it is devoid of strong transforming properties.
Two of the JAK3 mutants are present in cell lines. Both cell
lines harboring JAK3 mutations (CMK and CMY) exhibited
constitutive STAT5 and JAK3 tyrosine phosphorylation and were
sensitive to the JAK inhibitor I, indicating that JAK3A572V and
JAK3A573V were bona fide activating mutations (Figure S2). All
3 mutations were expressed in BaF3 cells. JAK3A572V and
JAK3A573V readily transformed BaF3 cells to IL3 independency,
whereas JAK3V722I induced cell growth, albeit in a delayed
fashion (Figure 2). Detailed analyses of JAK3A572V and
JAK3V722I have been reported elsewhere,21 and JAK3A573V was
assumed to behave similarly to JAK3A572V (Figure 3B).
Using this assay, MPLT487A was compared with MPLWT and
MPLW515L. MPLT487A and MPLW515L were able to induce
BaF3 growth in the absence of IL3. Accordingly, Stat5, Erk1/2, and
Akt were constitutively phosphorylated in MPLT487A cells, as
judged by Western blot analysis (Figure 3C). This result indicated
that transformation by MPLT487A was associated with activation
of the main signaling pathways normally activated by MPL.
The substitution of a threonine by an alanine resulted in both
structural and polarity changes at this position. In several other
Figure 2. Analyses of the candidate mutations in BaF3 cells. (A) JAK2M535I does not induce the growth of BaF3 cells in the absence of IL-3. (B) JAK3A573V induces
IL-3–independent growth of BaF3 cells. The growth of JAK3V722I cells is observed at later time points. (C) Expression of MPLT487A results in IL-3–independent growth of
BaF3 cells. MPLT487A induces IL-3–independent growth of BaF3 cells slightly later than MPLW515L does; MPLT487V is not able to induce growth in these conditions. Two
independent experiments, each in triplicate, were performed, and the mean plus or minus SD of 1 representative experiment is shown.
Figure 3. Activation of signal transduction pathways by JAK2, JAK3, and MPL mutants. Studies of Stat5, Erk1/2, and Akt phosphorylation in the different BaF3 clones
expressing the mutant JAK2 (A), JAK3 (B), and MPL (C) proteins.
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species, such as mouse, a serine replaces this threonine. To test
whether both structural and polar changes were important, we
created an artificial mutant in which threonine was changed to
valine, thereby maintaining the structure, but losing the polarity.
When tested in BaF3 cells, the mutant MPLT487V was not able to
induce BaF3 growth in the absence of IL3. This result indicates an
important role of the beta-branched side chain structure (implying a
certain degree of imposed rigidity) for the amino acid residue at
this position for maintaining the unliganded human MPL inactive.
We next wanted to assess the in vivo effects of MPLT487A.
Bone marrow cells from BALB/c mice were transduced with
MSCV-GFP vectors containing MPLWT or MPLT487A and were
engrafted in lethally irradiated recipients. The MPLW515L mutant
was included for comparison purposes.
MPLW515L-transduced mice developed a myeloproliferative
disease with a short latency (median survival: 14 days) as
previously reported.6 As shown in Figure 4A, MPLT487A-
transduced mice developed a similar disease, albeit with a longer
latency (median survival: 27.5 days; P  .008). The disease was
associated with thrombocytosis, leukocytosis, and splenomegaly
(Figure 4B,C). Histopathology analysis was consistent with the
presence of a MPD in MPLT487A- and MPLW515L-expressing
mice, and staining of bone marrow evidenced an increased reticulin
fiber network leading to a mild myelofibrosis in both cohorts of
engrafted mice, but not in MPLTWT-transduced mice (Figure S3).
Flow cytometric analyses of bone marrow and spleen cells of the
transduced animals are shown Figure 4D. MPLT487A samples
showed an increase of mature myeloid cells (Mac1Gr1) in both
tissues, compared with MPLWT-transduced animals. Amplification
of the immature erythroid compartment (CD71Ter119) was also
observed in both bone marrow and spleen. A strong amplification
of more mature erythroid cells (CD71Ter119) was observed
specifically in the spleen of MPLT487A, with respect to MPLWT
and MPLW515L. The percentage of CD41/CD42 cells was
increased in bone marrow and spleen of MPLT487A, reflecting an
amplification of the megakaryocytic lineage.
The MPLW515L is able to sustain cytokine-independent my-
eloid colony growth.6 To investigate this property in MPLT487A-
expressing cells, cellular suspensions from the killed mice were
tested for colony growth in vitro, either in the presence or in the
absence of cytokines. When isolated from bone marrow or from
spleen, cellular suspensions from MPLT487A-transduced mice
were able to generate colonies in the presence of cytokines (Figure
5A,B). Similarly, MPLW515L samples generated myeloid colonies
from bone marrow and spleen, whereas almost no colonies were
observed from spleen of mice engrafted with MPLWT-transduced
cells. In the absence of cytokine, only MPLT487A- and
MPLW515L-expressing progenitors were able to generate colonies
irrespective of their bone marrow or spleen origin.
To perform a specific analysis of megakaryocytic progenitors, bone
marrow suspensions were seeded in specific megakaryocytic conditions
(Figure 5C). In these conditions, the number of colonies was higher in
MPLT487A than MPLWT animals. In addition, the size of these
colonies was much larger compared with MPLWT (Figure 5D).
Taken together, our results show that, similarly to MPLW515L,
MPLT487A induces a myeloproliferative disorder in the mice and is
able to sustain cytokine-independent growth of myeloid cells in vitro,
thereby establishing that MPLT487A is a bona fide activating mutation.
Figure 4. Comparison of BALB/c mice engrafted with bone marrow cells transduced with MPLT487A, MPLW515L, and MPLWT. (A) Kaplan-Meier survival plot of
recipient BALB/c mice expressing MPLWT (n  6), MPLW515L (n  3), and MPLT487A (n  6). MPLWT mice were killed without signs of disease. (B) Blood count analysis.
MPLWT (n  6), MPLW515L (n  3), and MPLT487A (n  6). (C) Splenomegaly in MPLW515L (n  3) and MPLT487A (n  5) mice. The spleens of 4 MPLWT mice were
weighted for comparison purposes. Error bars denote SD. (D) Flow cytometric analysis of bone marrow cell suspensions (left panel) and spleen cell suspensions (right panel).
It shows an increase of granulocytic cells (Mac1Gr1; first row) and of immature erythroid populations (CD71/Ter119; second row) and an amplification of the
megakaryocytic lineage (CD41/CD42; third row), when MPLT487A-transduced cells are compared with the others. These analyses are representative of several: MPLWT
(n  3), MPLW515L (n  1), and MPLT487A (n  4).
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Discussion
AMKL can develop either de novo or as a transformation of MPD.
Transformation of megakaryoblastic progenitor is a multistep
process that remained poorly understood because of the very
limited access to primary cells. We investigated the status of a set of
genes mutated in human AML and MPD and encoding molecules
involved in tyrosine kinase signaling in a series of human AMKL
samples, from DS and non-DS patients. In addition to oncogenic
mutations within JAK2, FLT3, and KIT, we identified nonsynony-
mous nucleotide changes in JAK2, JAK3, and MPL, which were not
readily attributable to known polymorphisms.
It seems from the sequence data that the JAK2V617F mutation
is present at low level, suggesting its presence in a minor clone. The
shortage of material prevented any accurate quantification of the
mutation in our samples. However, this observation suggests that
JAK2V617F only weakly cooperates with 21 and GATA1s.
We observed a JAK3V722I in a DS-AMKL patient, a nonsyn-
onymous nucleotide change repeatedly reported in similar patients.
As previously reported,21 the mutant protein transforms BaF3 cells
in a delayed fashion, compared with the other mutations. The exact
role of this mutation in transformation remains elusive.
The JAK3A573V possesses hallmarks of a gain-of-function
mutation: the protein is constitutively tyrosine phosphorylated;
supports the growth of CMY, the cell line endogenously expressing
JAK3A573V; is sensitive to JAK tyrosine kinase inhibitors; and
induces IL3-independent growth of BaF3. Two independent descrip-
tions of the same mutation in primary cells of DS-AMKL were
recently reported,30,31 indicating that this is not a cell line artifact.
Taken together, our data strongly support the recurrent participation
of JAK activating mutations in DS leukemogenesis.21,26,32
Examination of patient 69, the unique non–DS-AMKL patient with
an FLT3 mutation, showed that he harbored an additional chromosome
21 and a mutated GATA1 gene.25 Therefore, our results strengthen the
proposed oncogenic cooperation between tyrosine kinase signaling and
GATA1s in a 21 context.33 Such a cooperation may be related to the
fact that GATA1s induces an increased proliferation of fetal but not of
adult MK progenitors.16 Therefore, acquisition of a tyrosine kinase
mutation might be required in the transformation of GATA1s cells
because a switch from fetal to adult hematopoiesis seems to occur
during the first year of life.
We report a novel mutation with the MPL cytokine receptor in a
non–DS AMKL patient. This mutation was not observed in a small
series of 30 AML samples (data not shown and Table S1), indicating it
might be specific for megakaryoblastic diseases. Study of the MPLT487A
mutant showed that it was able to induce a myeloproliferative disease in
mice, underscoring a link between MPD and AMKL.
The exact mechanism by which MPLT487A induces MPL
signaling will need to be investigated. The targeted threonine is
predicted to be situated in the extracellular domain of MPL, close
to the membrane, in a position symmetrically opposite to W515,
the amino acid mutated in MPD6,8,9,34 (Figure 5E). It has been
shown that W515 mutations affect an amphipathic alpha-helix and
induce a change in receptor conformation and constitutive activa-
tion.34 The 2 types of mutations, T487A and W515L/K, affecting
residues flanking the MPL transmembrane domain, might abolish
mechanisms that maintain the unliganded MPL inactive, possibly by
allowing productive dimerization of MPL and activation of JAK2. The
myeloproliferative diseases induced by MPLT487Aand W515L appear,
however, slightly different. The MPLT487A-induced disease had milder
progression with the presence of an important erythroid participation.
This suggests subtle differences in signaling between the 2 mutants.
Finally, our findings suggest that a more expansive genomic screen for
Figure 5. In vitro analysis of MPLT487A cells. (A) Growth of myeloid colonies from bone marrow cells in the presence () or the absence () of cytokines. MPLW515L- and
MPLT487A-transduced, but not MPLWT-transduced, cells are able to generate myeloid colonies in the absence of cytokines. Two MPLW515L, 5 MPLT487A, and 3 MPLWT
animals were analyzed. (B) Growth of myeloid colonies from spleen cellular suspensions in the presence () or absence () of cytokines. Consistent with the observed
splenomegaly, MPLW515L and MPLT487A mice generate myeloid colonies in the presence or absence of cytokines. Two MPLW515L, 5 MPLT487A, and 3 MPLWT animals
were analyzed. (C) Megakaryocytic progenitor colony assays. Bone marrow samples of MPLT487A mice generated more megakaryocytic colonies than bone marrow from
MPLWT mice (P  .01). Two MPLW515L, 5 MPLT487A, and 4 MPLWT animals were analyzed. Error bars denote SD. (D) Acetylcholine staining of the megakaryocytic
colonies. As for MPLW515L, megakaryocytic colonies from MPLT487A mice were larger than those from MPLWT mice. (E) Alignment of human (top) and mouse (bottom) MPL
proteins. Amino acids 474 to 522 (NP 005364) are shown for the human MPL protein and 465 to 513 (NP 034953) for the mouse MPL. The predicted transmembrane region
is boxed. Arrowheads indicate the amino acids mutated in human hematologic malignancies. Immunohistochemistry-stained sections were examined under a Leica DMLB
microscope (Leica, Heidelberg, Germany) equipped with a 10 eyepiece and a 10/0.40 CS HC PL APO objective lens. Images were captured with a Sony Power HAD
camera (Sony France, Paris, France) and imaging was performed with the version 1.4 software TRIBVN-ICS (Image Communication Software, Chatillon, France) and Adobe
Photoshop version 7.0 software (Adobe Systems, San Jose, CA).
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involvement of other components of the JAK-STAT signaling pathway
is warranted in AMKL.
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